Treatment for relapsed acute promyelocytic leukemia: what is the best post-remission treatment?

ABSTRACT:

Background

Arsenic trioxide (ATO) is the standard treatment for relapsed acute promyelocytic leukemia (APL). However, consensus on post-remission therapies is still lacking.

Methods

We evaluated 52 patients who experienced relapse following initial treatment of APL between 2000 and 2019 at Catholic Hematology Hospital. Among them, 41 patients received reinduction treatment, 30 with ATO-based regimen, whereas 11 with conventional intensive chemotherapy (IC).

Results

The ATO reinduction group showed a significantly higher second molecular complete remission (mCR2) rate, superior neutrophil and platelet recovery, and a lower infection rate than the IC reinduction group. No significant differences were observed in survival outcomes after post-remission treatment among the

SUBMITTER: Min GJ 

PROVIDER: S-EPMC9492525 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature